Clinical trialNAWithdrawn
A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer
- Outcome
- Stopped earlyNo accrual (Enrollment)
- Phase
- NA
- Status
- Withdrawn
- Study type
- Interventional
- Start
- January 2014
- Expected end
- October 2014
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- Sponsor
- Other
- Results posted
- No
- Last update
- 9 June 2016
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Pancreatic cancer is considered a rare form of cancer with about 277,000 new cases diagnosed in 2008 world-wide, which is about 2.5% of all forms of cancer. However, pancreatic cancer is more common in developed countries where the rate of this tumor is on the rise compared to other types of cancer. LDE225 is a new medicine that blocks a cellular pathway (called Hedgehog pathway) that is thought to be changed in some patients with pancreatic cancer. LDE225 is a medicine which has not been approved by the FDA for the treatment of people with your medical condition. The medicine being tested in this study is currently not "on the market" (available to buy) in any country. The purpose of this study is to see the effect LDE225 has on blood and tumors.